KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: a systematic review. PMID 39619239 · EClinicalMedicine · 2024-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial. PMID 39608305 · ESMO Open · 2024-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia. PMID 39601658 · Clin Transl Sci · 2024-Dec The record describes a pharmacokinetic analysis from a Phase 3 trial but does not present the primary or key secondary time-to-event efficacy results (e.g., OS, PFS) with associated KM or HR. It is therefore excluded based on the time_to_event criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tislelizumab for consolidation therapy in patients with pathologically residual Esophageal Squamous Cell Carcinoma after definitive concurrent Chemoradiotherapy: a multicenter, randomized, controlled phase II trial. PMID 39589855 · Future Oncol · 2024-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparative effectiveness and safety of imported and domestic immune checkpoint inhibitors in China: A systematic review and pairwise and network meta-analyses. PMID 39571771 · Pharmacol Res · 2024-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect of Opioid-Free General Anesthesia Versus Opioid-Based General Anesthesia on Postoperative Pain and Immune Response in Patients Undergoing Breast Cancer Surgery: A Randomized Controlled Trial. PMID 39555352 · Indian J Surg Oncol · 2024-Dec Study is a randomized trial in breast cancer patients, but it is not a Phase III/IIIb or Phase II/III trial (phase not specified), and its primary endpoint is postoperative morphine consumption, not a time-to-event efficacy endpoint like OS, PFS, or DFS. The intervention is an anesthetic technique (opioid-free vs. opioid-based anesthesia), which is not a drug-containing oncologic intervention. Therefore, it does not meet the criteria for a definitive oncology KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A pilot randomized clinical trial of a smartphone-based application to support at-home PSA screening and culturally tailored prostate cancer education for African American men: A study protocol. PMID 39532237 · Contemp Clin Trials · 2024-Dec The record is a study protocol for a pilot randomized trial. While it is oncology-related and randomized, it fails multiple key eligibility criteria: it is not a Phase III/IIIb or definitive Phase II/III trial; the intervention is non-drug (mHealth app and education); and the outcomes are knowledge and screening uptake, not time-to-event efficacy endpoints. It is a protocol without results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer. PMID 39530627 · Future Oncol · 2024-Dec While the record describes an oncology randomized Phase III trial with a drug intervention and original results, the abstract does not explicitly report a primary or key secondary time-to-event efficacy endpoint suitable for KM digitization (e.g., OS, PFS, DFS with KM curves or HR). The 6-month PFS rate is a snapshot, not a time-to-event analysis with reported KM data or HR.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years. PMID 39522957 · J Dermatolog Treat · 2024-Dec The record describes a randomized, Phase III trial of baricitinib, but the indication is atopic dermatitis, which is a non-oncologic, dermatologic condition. Furthermore, the primary efficacy endpoint reported is the proportion of responders achieving vIGA-AD 0/1 at a specific time point (Week 52), not a time-to-event (survival) analysis.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Current Standards and Controversies in Multidisciplinary Management of Locoregional Gastroesophageal Junction Tumors. PMID 39508985 · Curr Oncol Rep · 2024-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A single center prospective phase II clinical trial. PMID 39488901 · Oral Oncol · 2024-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation. PMID 39476445 · Eur J Cancer · 2024-Dec This is a methodological study using real-world data to emulate 8 existing randomized controlled trials (RCTs). It is not a report of an original randomized trial with drug intervention results. The publication type is a journal article presenting a methodological validation, not a primary clinical trial report. While it discusses RCTs, it does not present the results of a single, original Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study. PMID 39446605 · Cancer Commun (Lond) · 2024-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study. PMID 39442371 · Gynecol Oncol · 2024-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Subclinical cardiac damage monitoring in breast cancer patients treated with an anthracycline-based chemotherapy receiving left-sided breast radiation therapy: subgroup analysis from a phase 3 trial. PMID 39436588 · Radiol Med · 2024-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Volumetric evaluation of autologous fat transfer for total breast reconstruction. PMID 39413587 · J Plast Reconstr Aesthet Surg · 2024-Dec 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Breast induration and irradiated volume in the DBCG HYPO trial: The impact of age, smoking, and boost. PMID 39395667 · Radiother Oncol · 2024-Dec The study is a Phase III randomized oncology trial with original results, but it does not involve a drug-containing intervention (it compares radiotherapy schedules) and does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary outcome is breast induration, a toxicity/quality-of-life endpoint, not an efficacy time-to-event endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Active symptom monitoring for premenopausal women with breast cancer initiating adjuvant endocrine therapy: Protocol for the SWOG S2010 randomized controlled efficacy trial. PMID 39395534 · Contemp Clin Trials · 2024-Dec 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Axillary clearance and chemotherapy rates in ER+HER2- breast cancer: secondary analysis of the SENOMAC trial. PMID 39386258 · Lancet Reg Health Eur · 2024-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
High efficacy of red light photodynamic therapy with 10 % aminolevulinic acid gel irrespective of the extent of keratinocyte atypia in actinic keratosis - exploratory post-hoc analysis of three pivotal phase III trials. PMID 39384092 · Photodiagnosis Photodyn Ther · 2024-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. PMID 39373062 · Eur J Neurol · 2024-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prognostic Impact of Bone Metastasis in Patients With Metastatic Urothelial Carcinoma Treated With Durvalumab With or Without Tremelimumab in the DANUBE Study. PMID 39353213 · Clin Genitourin Cancer · 2024-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The EORTC 22922/10925 trial investigating regional nodal irradiation in stage I-III breast cancer: Outcomes according to locoregional and systemic therapies. PMID 39341505 · Radiother Oncol · 2024-Dec The study is a secondary analysis of a randomized trial (EORTC 22922/10925) focused on the effect of radiation therapy. While it includes time-to-event endpoints (DFS, OS) and drug therapies are mentioned as part of the analysis, the primary intervention is non-drug (radiation), and the report is not the primary result of a drug-containing Phase III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials. PMID 39322715 · Leukemia · 2024-Dec While the record describes a comparison of two phase 3 randomized oncology trials, the title and provided metadata lack any signal of a time-to-event efficacy endpoint (KM curves, HR, or specific survival outcomes). It is also a retrospective comparative study, not an original result report of a single trial. Therefore, it does not meet all eligibility criteria.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The effect of purslane supplementation on clinical outcomes, inflammatory and antioxidant markers in patients with rheumatoid arthritis: A parallel double-blinded randomized controlled clinical trial. PMID 39306881 · Phytomedicine · 2024-Dec Study evaluates a dietary supplement (purslane) for rheumatoid arthritis, not an oncology clinical trial. No drug-containing intervention (dietary supplement, not a standard drug). No time-to-event efficacy endpoint (OS, PFS, DFS, etc.) reported; outcomes are continuous inflammatory/clinical measures. Thus, it fails multiple key eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial. PMID 39305910 · Lancet Respir Med · 2024-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial. PMID 39303189 · J Clin Oncol · 2024-Dec The study is a randomized trial for human oropharyngeal cancer with a drug-containing arm (chemotherapy) and reports time-to-event efficacy endpoints (OS, PFS). However, the explicit trial phase is not stated in the provided metadata, and the primary endpoint is quality of life, not a formal efficacy endpoint as defined by the criteria (though secondary efficacy endpoints are reported). Therefore, is_eligible is false due to unclear phase evidence and the primary endpoint not being an efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT Study. PMID 39284385 · J Thromb Haemost · 2024-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Intra-prostatic recurrences after radiotherapy with focal boost: Location and dose mapping in the FLAME trial. PMID 39278316 · Radiother Oncol · 2024-Dec The record is an original research article describing a subgroup analysis of the FLAME trial, focusing on the location and dose mapping of intraprostatic recurrences after radiotherapy. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with KM curves or HR. The intervention is radiotherapy with a focal boost, not a drug-containing intervention. While the parent FLAME trial is a randomized Phase III trial, this specific report is not the primary trial report and does not meet the criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. PMID 39277672 · Nat Med · 2024-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. PMID 39271844 · Nat Med · 2024-Dec The study is a phase 3b/4 oncology trial with a drug intervention and reports primary time-to-event efficacy (PFS), but it is a single-arm, non-randomized trial, which is excluded from the cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study. PMID 39270695 · Lancet Respir Med · 2024-Dec The study is a single-arm Phase 3b trial, which fails the randomized criterion. Furthermore, the primary efficacy endpoint is objective response rate (ORR), a response rate metric, not a time-to-event endpoint such as overall survival, progression-free survival, or others specified for inclusion. Therefore, it does not meet the eligibility criteria for a randomized trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma. PMID 39268981 · Hematology · 2024-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial. PMID 39266383 · Eur Urol · 2024-Dec The trial is a Phase 3 randomized oncology trial with original results, but it compares two non-drug interventions (stereotactic body radiotherapy vs. prostatectomy) and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or Kaplan-Meier/HR for such an endpoint. The primary endpoints are patient-reported quality-of-life outcomes.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of tacrolimus versus cyclosporine after lung transplantation: an updated systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials. PMID 39261378 · Eur J Clin Pharmacol · 2024-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy of Wuda Granule on Recovery of Gastrointestinal Function after Laparoscopic Bowel Resection: A Randomized Double-Blind Controlled Trial. PMID 39251465 · Chin J Integr Med · 2024-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Serum Androgens as Predictive Biomarkers: Results From a Randomized Clinical Trial Comparing Enzalutamide and Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer. PMID 39244832 · Clin Genitourin Cancer · 2024-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-Term Outcome of Low- and High-Dose Radioiodine for Thyroid Remnant Ablation. PMID 39233456 · Clin Endocrinol (Oxf) · 2024-Dec The study is a randomized clinical trial in human oncology with time-to-event endpoints (recurrence, survival). However, the intervention is radioiodine for ablation, which is a radiopharmaceutical and may not meet the 'drug-containing intervention' criterion if interpreted strictly as systemic therapy. Furthermore, the trial phase is not specified as Phase III or equivalent in the provided metadata or abstract, failing the 'phase3_or_definitive' requirement.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. PMID 39233312 · Ann Oncol · 2024-Dec 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Healthy Eating and Active Lifestyle after Bowel Cancer (HEAL ABC)-feasibility randomised controlled trial. PMID 39191956 · Eur J Clin Nutr · 2024-Dec This is a feasibility randomized controlled trial of a lifestyle intervention in post-colorectal cancer patients. It is not a Phase III or definitive efficacy trial, does not involve a drug intervention, and does not report a primary/key secondary time-to-event endpoint (e.g., OS, PFS, DFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The EXcellenT Trial: Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment. PMID 39191545 · Clin Lung Cancer · 2024-Dec The record is a clinical trial protocol for a randomized study in oncology patients receiving TKIs. However, it is not a Phase III/IIIb or Phase II/III trial (phase is not specified as definitive), and it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The study's primary aim is to evaluate quality of life and performance, with exploratory biomarker goals. It is a protocol, not a report of trial results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of hepatic arterial infusion chemotherapy combined with donafenib in the treatment of unresectable hepatocellular carcinoma. PMID 39183450 · Asia Pac J Clin Oncol · 2024-Dec Phase information is not explicitly stated in the provided metadata. The record is labeled as a Randomized Controlled Trial, and the title/abstract describe a clinical study, but the trial phase (Phase II/III or Phase III/IIIb) is not mentioned. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Wesley R. Armstrong, Amar U. Kishan, Kiara M. Booker, et al. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol 2024;86:52-60. PMID 39174410 · Eur Urol · 2024-Dec 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations. PMID 39159418 · J Clin Oncol · 2024-Dec The record describes the primary analysis of a randomized Phase III trial (CAPItello-291) with a PFS endpoint. However, the provided abstract is an FDA approval summary that reports the trial results in a secondary, regulatory context, not the original primary report from the trial investigators. Therefore, it does not meet the 'original_result' criterion for this adjudication.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results. PMID 39159403 · J Clin Oncol · 2024-Dec The record is eligible as a formal report of a human oncology randomized trial with drug intervention and primary time-to-event endpoints. The phase is not explicitly labeled 'Phase III' in the provided text, but the trial's design, scale, and definitive nature satisfy the 'phase3_or_definitive' criterion.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PMID 39151115 · J Clin Oncol · 2024-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
An Integrated Approach Using Network Pharmacology and Experimental Validation to Reveal the Therapeutic Mechanism of Weifuchun in Treating Gastric Cancer. PMID 39142714 · J Med Food · 2024-Dec The study is an oncology RCT with a drug intervention and original results, but it does not meet all required criteria for eligibility: the phase is not specified as Phase III/IIIb or II/III (cannot be inferred), and the primary endpoint is recurrence and metastasis rates, not a time-to-event endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A randomized controlled study of neoadjuvant metformin with chemotherapy in nondiabetic breast cancer women: The METNEO study. PMID 39113190 · Br J Clin Pharmacol · 2024-Dec The study is a randomized trial in oncology with a drug intervention and reports original results, but it lacks an explicit primary or key secondary time-to-event efficacy endpoint (like OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR. The endpoints reported are clinical/pathological response rates and biomarker expressions, which are not time-to-event. The phase is not specified in the abstract.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer. PMID 39083190 · Breast Cancer Res Treat · 2024-Dec The record describes a randomized trial in human oncology with drug intervention and time-to-event endpoints, but the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata or text. The abstract and metadata do not specify the phase, and the deterministic review flagged phase as unclear. Without explicit confirmation of the trial phase, the eligibility criterion is not met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial. PMID 39038562 · J Heart Lung Transplant · 2024-Dec The study is a randomized, long-term follow-up report of a trial in heart transplant recipients (non-oncology). While it reports survival (a time-to-event endpoint), it is not an oncology trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -